Degenhardt, Thorsten

Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections

Martens, M. G., Maximos, B., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., Flynt, A., & Brand, S. R. (2022) · American Journal of Obstetrics and Gynecology

Antifungal resistance and susceptibilityReproductive tract infections research

Cited by 86

A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis

Brand, S. R., Degenhardt, T. P., Person, K., Sobel, J. D., Nyirjesy, P., Schotzinger, R. J., & Tavakkol, A. (2018) · American Journal of Obstetrics and Gynecology

Antifungal resistance and susceptibilityReproductive tract infections research

Cited by 78

A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis

Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityReproductive tract infections research

Cited by 61

Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis

Sobel, J. D., Donders, G., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., & Brand, S. R. (2022) · NEJM Evidence

Antifungal resistance and susceptibilityReproductive tract infections research

Cited by 55

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*

Elewski, B., Brand, S., Degenhardt, T., Curelop, S., Pollak, R., Schotzinger, R., Tavakkol, A., Alonso‐Llamazares, J., Ashton, S. J., Bhatia, N., et al. (2021) · British Journal of Dermatology

Nail Diseases and TreatmentsAntifungal resistance and susceptibility

Cited by 42